Zealand reports Lyxumia® royalty revenue for Q3 2015 and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand reports Lyxumia® royalty revenue for Q3 2015 and that Sanofi confirms expected next steps in the US regulatory process

Copenhagen, 2015-10-29 08:17 CET (GLOBE NEWSWIRE) --

  • Royalty revenue to Zealand from Sanofi’s sales of Lyxumia ® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9 million in Q3 2015, a 20% increase over Q3 2014
  • A US regulatory decision on lixisenatide by the FDA is expected in Q3 2016
  • Sanofi expects regulatory submission of LixiLan in Q4 2015 in the US and in Q1 2016 in Europe

Copenhagen, 29 October 2015 – Zealand announces that royalty revenue on Sanofi’s global sales of Lyxumia ® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9 million for the period 1 July to 30 September 2015. This corresponds to an increase of 20% over the same period in 2014. Royalties were at the same level as for the previous quarter, after an increase of 12% from the first to the second quarter in 2015. Royalty revenue for the first nine months of 2015 amounted to DKK 20.5 million / EUR 2.7 million, which corresponds to an increase of 46% compared to the same period in 2014.

Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of Type 2 diabetes, invented by Zealand, developed and commercialized by Sanofi under a global license agreement. Lixisenatide is approved outside the US under the tradename Lyxumia ® and the product is currently available for patients in 40 countries with further launches planned later in 2015.

In September 2015, the Food and Drug Administration (FDA) accepted for filing Sanofi’s New Drug Application (NDA) for lixisenatide in the US, and a regulatory decision is expected in Q3 2016.

For LixLan, the fixed-ratio combination of lixisenatide and insulin glargine (Lantus ® ) for Type 2 diabetes, Sanofi expects to submit for regulatory approval in Q4 2015 in the US and in Q1 2016 in Europe.  

In a comment to this announcement, Britt Meelby Jensen, President and CEO at Zealand, said : “ Lixisenatide is an important product in Zealand’s portfolio, in particular combined with insulin glargine in the LixiLan combination product. We value our license collaboration with Sanofi, which today has re-confirmed the important expected next steps in the regulatory process for lixisenatide in the US and for LixiLan in the US and in Europe.”

Financial guidance for 2015 and terms of the license agreement with Sanofi

Zealand maintains its financial guidance for 2015, including increasing lixisenatide royalty revenue and expected milestone payments from license partners of up to DKK 155 million (EUR 21 million). Full year net operating expenses are expected to be at a range of DKK 225-235 million (EUR 30-32 million).

Under the global license agreement with Sanofi, covering lixisenatide (Lyxumia ® ) and any combination products, which include lixisenatide, Sanofi is responsible for all development and commercialization including the financing, while Zealand is eligible to receive progress-driven milestone payments and royalties on global sales. Remaining milestone payments amount up to USD 160 million, while royalty payments correspond to tiered, low double-digit percentages of Sanofi's global sales of Lyxumia ®  plus fixed low double-digit percentages of global full net sales of LixiLan.

●●●●●

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a medicinal biotech company with leading expertise in the identification, design and development of novel peptide medicines. Zealand has a proprietary pipeline of novel drug candidates and a portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim – primarily in the fields of cardio-metabolic diseases and acute care indications.

The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development, ZP1848 for Short Bowel Syndrome in Phase II development and the stable glucagon analogue, ZP4207 as a single-dose rescue pen for severe hypoglycemia in preparation for Phase II, and ZP4207 as multiple-dose use for the correction of mild to moderate hypoglycemia in evaluation for the next clinical development step after Phase I, as well as several preclinical peptide therapeutics .

Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes and since end September 2015 has been under review by the FDA in the US. The license agreement with Sanofi also covers a fixed-ratio combination of lixisenatide and insulin glargine (Lantus ® ) which is on track for regulatory submission in the US in Q4 2015 and in Europe in Q1 2016.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 6

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Freedom Jet Card Launched by FlyUSA for Travelers

Updated Category News Views 311

FlyUSA Launches the Freedom Jet Card for Enhanced Travel FlyUSA is taking the world of private aviation to new heights with the introduction of its groundbreaking Freedom Jet Card. This innovative service brings a fresh approach to private flying, offering travelers the assurance of predictable pricing combined with unmatched flexibility and a wide array of aircraft...

Continue Reading
Enovix Corporation's Recent Stock Offering: A Game Changer

Updated Category News Views 104

Enovix Corporation's Public Offering Overview Enovix Corporation, a leader in high-performance battery technology, has recently announced an underwritten public offering of 10,416,667 shares of its common stock. This initiative is expected to generate gross proceeds of around $100 million, paving the way for critical advancements in their production capabilities. The...

Continue Reading
HP, First Solar, Workday Facing Headwinds as Stocks Slide

Updated Category News Views 208

Markets in Motion: A Peek at Pre-Market Action The stock market's a fickle beast, isn’t it? The Dow futures are looking moderately optimistic, gaining about 0.1% this morning. But don’t let that sunshine fool you; beneath the surface, some big names are taking hits as investors reposition themselves. HP's Disappointing Movement HP Inc. just reported its quarterly...

Continue Reading
Outset Medical Faces Class Action Amid Earnings Shortfalls

Updated Category News Views 182

Outset Medical’s Legal Challenges and Market Response Outset Medical, Inc. (NASDAQ: OM) is currently facing class action litigation, which has raised concerns among its investors. The situation arose after the company disclosed significant operational challenges and regulatory issues that have impacted its stock performance significantly. Class Action Overview Pomerantz...

Continue Reading
Schneider Electric Showcases Sustainability at Climate Week

Updated Category News Views 80

Schneider Electric's Commitment to Sustainability at Climate Week NYC Schneider Electric is making significant strides in promoting sustainability during Climate Week NYC. The company is dedicated to a thorough approach to energy transition that fosters collaboration among various sectors. This effort isn't just about encouraging eco-friendly practices; it represents a...

Continue Reading